Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm - Test2 - elhamkhani - TriplyDB

Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm

Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm

http://www.wikidata.org/entity/Q26779936

about

Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study.Carotid Artery Stiffness, Digital Endothelial Function, and Coronary Calcium in Patients with Essential Thrombocytosis, Free of Overt Atherosclerotic Disease.Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly

P2860

Q39986585-6E1F4E5C-049E-40A8-8024-304EA304BC3D Q40489397-C7F2CF21-B909-41A1-8F66-DD2B952C0BDD Q40564541-F96B7529-358C-401D-8F5A-39CCEA4D92C3

P2860

Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm

http://www.wikidata.org/entity/Q26779936

description

2015 nî lūn-bûn

@nan

2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm

@ast

Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm

@en

Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm

@nl

type

label

Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm

@ast

Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm

@en

Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm

@nl

prefLabel

Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm

@ast

Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm

@en

Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm

@nl

P1433

Q26779936-1C075ED0-2EE0-4453-B8D8-66559116A566

P1476

Q26779936-F66818A2-8A42-4A97-84AC-59D72106949F

P2093

Q26779936-F2DB15BF-1616-47B7-8766-387208ED6995

P275

Q26779936-1EC542AB-1C37-4EC3-A806-0C6C593D72C7

P2860

Q26779936-1174296F-2C10-4623-8574-BF90C5562CED

Q26779936-1A28C934-5572-42B3-B3B3-CB818184BC0F

Q26779936-1C4C1C28-178F-4249-AF28-C8C6C93500E2

Q26779936-1DD944F7-E801-4741-8ABB-3BD163FD16A0

Q26779936-36A46BC6-BC66-4269-A037-E78E9DC2CDA9

Q26779936-4C0061BB-93BB-47C2-91F7-A1D2DAB1C83B

Q26779936-570FC692-97BF-496C-88CA-87179186EECE

Q26779936-5A1B2324-B10E-4A99-A0D1-851F1AA637B1

Q26779936-66EA9342-8ACD-48E0-BA51-E181E3F44C72

Q26779936-6D59C470-6872-4CE6-BF6C-4527B05C2727

P304

Q26779936-83B4FFA9-5ADA-49B8-BB71-4D492155E653

P31

Q26779936-1631AFFE-4D94-453C-AB07-CC5E558AC951

Q26779936-79E13F2A-A19F-4890-8D66-86DA210DBF21

P3181

Q26779936-1C31697A-0AD9-4EFA-BFE3-5B094DF5FA04

P356

Q26779936-C6236B1C-1353-4700-93B0-04CD40FF0E51

P407

Q26779936-54B88085-BD7C-4D43-BAEA-E4C2F9DFB3D4

P478

Q26779936-5A4DE9FF-7B7C-4B6C-AB18-16F4AB2716AA

P5008

Q26779936-B0148027-017E-4951-B3E6-EC590582C5D8

P577

Q26779936-A82703DB-905D-4EB0-B5CE-073EC567C127

P5875

Q26779936-4F76BE54-3E45-42EE-8F2C-76B3223E0E62

P698

Q26779936-96D7A852-9EBD-4873-9A78-1DDA87DE646A

P921

Q26779936-5DB28186-0D15-48BA-B31F-FC8DE7C839E8

Q26779936-81C8CAEE-E91C-4150-A596-AC52569584E5

Q26779936-E50E844A-A5B6-44CA-8CE8-2B532031DCE2

P932

Q26779936-D60B7C19-4307-46BB-9E66-D25987DEF55C

P3181

P356

P1433

Mediators of Inflammation

P1476

Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm

@en

P2093

Angela G Fleischman

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence

Age-related clonal hematopoiesis associated with adverse outcomes

Age-related mutations associated with clonal hematopoietic expansion and malignancies

Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2

MERIT40 deficiency expands hematopoietic stem cell pools by regulating thrombopoietin receptor signaling

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.

Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis.

Autoimmunity and the risk of myeloproliferative neoplasms.

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

P304

606819

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3609653

http://www.w3.org/2001/XMLSchema#string

P356

10.1155/2015/606819

http://www.w3.org/2001/XMLSchema#string

P407

P478

2015

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2015-10-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283236458

http://www.w3.org/2001/XMLSchema#string

P698

26538830

http://www.w3.org/2001/XMLSchema#string

P921

myeloproliferative disorders

P932

4619974

http://www.w3.org/2001/XMLSchema#string